利钠肽用于分类卒中后检测心房颤动的风险:BIOSIGNAL与PRECISE队列研究分析
该研究基于BIOSIGNAL队列621例缺血性卒中患者及PRECISE队列239例缺血性卒中或短暂性脑缺血发作患者,评估MR-proANP和NT-proBNP联合临床变量识别卒中后不太可能检出心房颤动者的价值。结果显示联合利钠肽可提高判别能力,并可能将需延长心脏监测的人数减少30%(临床+log10MR-proANP)、27%(临床+log10NT-proBNP)或20%(仅临床),而不减少检出心房颤动的数量。
要点
- 在BIOSIGNAL队列中,临床变量AUROC为0.68,加入log10MR-proANP后升至0.72(p=0.001),加入log10NT-proBNP后升至0.71(p=0.009)。
- 在PRECISE队列中,临床变量AUROC为0.68,加入log10NT-proBNP后升至0.73(p<0.001),加入log10MR-proANP后升至0.79(p<0.001)。
- 基于15%阈值概率的决策曲线分析显示,联合模型可分别减少30%、27%或20%的延长心脏监测人数(临床+log10MR-proANP、临床+log10NT-proBNP、仅临床)。
核心结论
- MR-proANP和NT-proBNP有助于分类缺血性卒中后不太可能检出心房颤动的人群。
- 检测MR-proANP或NT-proBNP可能将需要延长心脏监测的人数减少30%,而不减少检出心房颤动的数量。
研究设计与样本
- 分析BIOSIGNAL研究中621例缺血性卒中、无已知心房颤动且心脏监测≥3天的患者。
- 在PRECISE研究中对239例缺血性卒中或短暂性脑缺血发作且无已知心房颤动的患者进行外部验证,监测28天。
主要发现
- BIOSIGNAL队列中临床变量AUROC为0.68(95%CI 0.62-0.74),加入log10MR-proANP后为0.72(0.66-0.78;p=0.001),加入log10NT-proBNP后为0.71(0.65-0.77;p=0.009);两模型性能相似(p=0.28)。
- PRECISE队列中临床变量AUROC为0.68(0.59-0.76),加入log10NT-proBNP后为0.73(0.65-0.82;p<0.001),加入log10MR-proANP后为0.79(0.72-0.86;p<0.001);log10MR-proANP模型优于log10NT-proBNP模型(p=0.03)。
关键数值与推荐
- 临床多变量预测模型包括年龄、NIH卒中量表评分、降脂治疗、肌酐和吸烟状态。
- 基于15%心房颤动检测阈值概率的决策曲线分析显示,联合模型可减少延长心脏监测人数:临床+log10MR-proANP减少30%,临床+log10NT-proBNP减少27%,仅临床减少20%。
临床怎么用
- 测量MR-proANP或NT-proBNP可能有助于优化卒中后延长心脏监测的靶向选择,减少需监测人数而不减少检出心房颤动的数量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Prolonged cardiac monitoring (PCM) increases atrial fibrillation (AF) detection after ischemic stroke, but access is limited, and it is burdensome for patients. Our objective was to assess whether midregional proatrial natriuretic peptide (MR-proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) could classify people who are unlikely to have AF after ischemic stroke and allow better targeting of PCM. METHODS: We analyzed people from the Biomarker Signature of Stroke Aetiology (BIOSIGNAL) study with ischemic stroke, no known AF, and ≥3 days cardiac monitoring. External validation was performed in the Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) study of 28 days of cardiac monitoring in people with ischemic stroke or transient ischemic attack and no known AF. The main outcome is no AF detection. We assessed the discriminatory value of MR-proANP and NT-proBNP combined with clinical variables to identify people with no AF. A decision curve analysis was performed with combined data to determine the net reduction in people who would undergo PCM using the models based on a 15% threshold probability for AF detection. RESULTS: We included 621 people from the BIOSIGNAL study. The clinical multivariable prediction model included age, NIH Stroke Scale score, lipid-lowering therapy, creatinine, and smoking status. The area under the receiver-operating characteristic curve (AUROC) for clinical variables was 0.68 (95% CI 0.62-0.74), which improved with the addition of log10MR-proANP (0.72, 0.66-0.78; p = 0.001) or log10NT-proBNP (0.71, 0.65-0.77; p = 0.009). Performance was similar for the models with log10MR-proANP vs log10NT-proBNP (p = 0.28). In 239 people from the PRECISE study, the AUROC for clinical variables was 0.68 (0.59-0.76), which improved with the addition of log10NT-proBNP (0.73, 0.65-0.82; p < 0.001) or log10MR-proANP (0.79, 0.72-0.86; p < 0.001). Performance was better for the model with log10MR-proANP vs log10NT-proBNP (p = 0.03). The models could reduce the number of people who would undergo PCM by 30% (clinical and log10MR-proANP), 27% (clinical and log10NT-proBNP), or 20% (clinical only). DISCUSSION: MR-proANP and NT-proBNP help classify people who are unlikely to have AF after ischemic stroke. Measuring MR-proANP or NT-proBNP could reduce the number of people who need PCM by 30%, without reducing the amount of AF detected. TRIAL REGISTRATION INFORMATION: NCT02274727; clinicaltrials.gov/study/NCT02274727.
引用
- Cameron AC, Arnold M, Katsas G, et al. Natriuretic Peptides to Classify Risk of Atrial Fibrillation Detection After Stroke: Analysis of the BIOSIGNAL and PRECISE Cohort Studies. Neurology. 2024. PMID: 38950311. doi:10.1212/WNL.0000000000209625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。